Natalizumab Re-Initiation of Dosing
An Open-Label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801, C-1802, or C-1803 and a Dosing Suspension Safety Evaluation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6T2B5
- Research Site
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H1V7
- Research Site
-
-
Ontario
-
Kingston, Ontario, Canada, K7L2V7
- Research Site
-
London, Ontario, Canada, N6A5A5
- Research Site
-
New York, Ontario, Canada, M4N 3M5
- Research Center
-
Ottawa, Ontario, Canada, K2G6E2
- Research Site
-
Toronto, Ontario, Canada, M5B1W8
- Research Site
-
-
Quebec
-
Gatineau, Quebec, Canada, J8Y1W7
- Research Site
-
Greenfield Park, Quebec, Canada, J4V2H1
- Research Site
-
Montreal, Quebec, Canada, H3A2B4
- Research Site
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Research Site
-
-
Arizona
-
Phoenix, Arizona, United States, 85006
- Research Site
-
Scottsdale, Arizona, United States, 85259
- Research Site
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- Research Site
-
-
California
-
Berkeley, California, United States, 94705
- Research Site
-
Los Angeles, California, United States, 90033
- Research Site
-
Redwood City, California, United States, 94063
- Research Site
-
Sacramento, California, United States, 95817
- Research Site
-
San Francisco, California, United States, 94117
- Research Site
-
-
Colorado
-
Colorado Springs, Colorado, United States, 80919
- Research Site
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Research Site
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Research Site
-
-
Florida
-
Maitland, Florida, United States, 32751
- Research Site
-
Miami, Florida, United States, 33136
- Research Site
-
Pompano Beach, Florida, United States, 33060
- Research Site
-
-
Georgia
-
Atlanta, Georgia, United States, 30327
- Research Site
-
-
Illinois
-
Arlington, Illinois, United States, 60007
- Research Site
-
Chicago, Illinois, United States, 60612
- Research Site
-
Chicago, Illinois, United States, 60637
- Research Site
-
Northbrook, Illinois, United States, 60062
- Research Site
-
-
Iowa
-
Des Moines, Iowa, United States, 50314
- Research Site
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- Research Site
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- Research Site
-
-
Massachusetts
-
Worcester, Massachusetts, United States, 01655
- Research Site
-
-
Michigan
-
East Lansing, Michigan, United States, 48824
- Research Site
-
Farmington Hills, Michigan, United States, 48334
- Research Site
-
-
New Jersey
-
Teaneck, New Jersey, United States, 07666
- Research Site
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87131
- Research Site
-
-
New York
-
Albany, New York, United States, 12208
- Research Site
-
Buffalo, New York, United States, 14203
- Research Site
-
Great Neck, New York, United States, 10019
- Research Site
-
New York, New York, United States, 10003
- Research Site
-
New York, New York, United States, 10319
- Research Site
-
Staten Island, New York, United States, 10305
- Research Site
-
Syracuse, New York, United States, 13202
- Research Site
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28207
- Research Site
-
Raleigh, North Carolina, United States, 27607
- Research Site
-
-
North Dakota
-
Fargo, North Dakota, United States, 58103
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- Research Site
-
Cleveland, Ohio, United States, 44195
- Research Site
-
-
Oregon
-
Portland, Oregon, United States, 97225
- Research Site
-
-
Pennsylvania
-
Allentown, Pennsylvania, United States, 18103
- Research Site
-
Philadelphia, Pennsylvania, United States, 19104
- Research Site
-
Philadelphia, Pennsylvania, United States, 19146
- Research Site
-
Pittsburgh, Pennsylvania, United States, 15213
- Research Site
-
Pittsburgh, Pennsylvania, United States, 15212
- Research Site
-
-
Tennessee
-
Memphis, Tennessee, United States, 38163
- Research Site
-
Nashville, Tennessee, United States, 37215
- Research Site
-
-
Texas
-
Dallas, Texas, United States, 75214
- Research Site
-
Round Rock, Texas, United States, 78681
- Research Site
-
-
Vermont
-
Burlington, Vermont, United States, 05401
- Research Site
-
-
Virginia
-
Charlottesville, Virginia, United States, 22903
- Research Site
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53215
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- MS subjects who completed Study C-1801 (NCT00027300), C-1802 (NCT00030966), or C-1803 (NCT00097760) and completed a Dosing Suspension Safety Evaluation (neurological examination and magnetic resonance imaging [MRI] scan)
- Considered by the investigator to be free of signs and symptoms suggestive of progressive multifocal leukoencephalopathy (PML) based on medical history, physical examination, or laboratory testing (results from the Dosing Suspension Safety Evaluation from Study C-1808 [NCT000276172] may be used)
- Other protocol-defined inclusion criteria may apply
Exclusion Criteria:
- Considered by the investigator to be immunocompromised, based on medical history, physical examination, or laboratory testing (results from the Dosing Suspension Safety Evaluation from Study C-1808 may be used), or due to prior immunosuppressive treatment
- History of persistent anti-natalizumab antibodies, based upon testing from prior natalizumab studies
- Other protocol-defined exclusion criteria may apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Natalizumab
All study participants in 101-MS-322 (NCT00306592) and 101-MS-321 (NCT00297232) received open label 300 mg intravenous (IV) natalizumab 60-minute infusion once every 4 weeks (28 days ±7 days) for up to 48 weeks.
After 48 weeks, participants from 101-MS-322 (NCT00306592) entering study 101-MS-321 (NCT 00297232; considered the Long-Term Treatment Period of 101-MS-322) were continued on treatment from Week 52 through Week 480.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious AEs (SAEs)
Time Frame: Baseline through Week 48
|
AEs: any sign, symptom, or diagnosis/disease that is unfavorable or unintended, that is new, or if pre-existing, worsens in participants administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment.
SAEs: an event that results in death; an event that, in the view of the investigator, places the participant at immediate risk of death (a life-threatening event); an outcome that results in a congenital anomaly/birth defect diagnosed in a child of a participant; an event that requires or prolongs inpatient hospitalization; an event that results in persistent or significant disability/incapacity.
Any other medically important event that, in the opinion of the investigator, may jeopardize the participant or may require intervention to prevent one of the other outcomes listed in the definition above.
Treatment-emergent AEs: events in participants who had received at least 1 dose of study drug, regardless of relationship to study drug.
|
Baseline through Week 48
|
|
Number of Participants With Hypersensitivity-related Adverse Events
Time Frame: Baseline through Week 48
|
For purposes of this analysis, the terms 'hypersensitivity' and 'drug hypersensitivity' were categorized by their temporal relationship to study drug infusion (within 2 hours of the start of the infusion), and were considered equivalent.
Hypersensitivity reactions are defined as infusion reactions with the following preferred terms: hypersensitivity not otherwise specified (NOS), anaphylactic reaction, anaphylactoid reaction, dermatitis allergic, drug hypersensitivity, urticaria NOS, vasoconstriction, urticaria generalised, hypersensitivity, urticaria.
|
Baseline through Week 48
|
|
Number of Participants With Antibodies to Natalizumab
Time Frame: Baseline (Week 0), Week 4, Week 24 (test was repeated after 8 weeks if positive, to confirm persistence)
|
'Positive with unknown persistence' is defined as a positive result (≥0.5 micrograms/mL) at one timepoint only with no confirmatory re-test available at least 42 days later.
'Transient positive' is defined as a positive at one timepoint but negative upon re-test at least 42 days later.
'Persistent positive' is defined as positive at 2 or more timepoints separated by at least 42 days.
The threshold for classifying a sample as 'antibody positive' was set at the lowest level of reactivity that had a measurable impact on drug serum concentrations.
|
Baseline (Week 0), Week 4, Week 24 (test was repeated after 8 weeks if positive, to confirm persistence)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Helpful Links
- (MSActiveSource.com is a resource for news, information, and disease management for all individuals touched by Multiple Sclerosis. This site is sponsored by Biogen Idec.)
- The website of the National Multiple Sclerosis Society, an organization dedicated to providing information to individuals with MS, their families, and healthcare providers.)
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Multiple Sclerosis
- Sclerosis
- Multiple Sclerosis, Relapsing-Remitting
- Physiological Effects of Drugs
- Immunologic Factors
- Natalizumab
Other Study ID Numbers
Other Study ID Numbers
- 101-MS-322
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.